Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Flagged first, then by citations

Show all 393 references

3 of the 393 references couldn’t be matched to a known paper.

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 301–400 of 998

Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action
Duncan, C. E., Chetcuti, A., & Schofield, P. R. (2008) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283053019 · Cited by 37
Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study
Atalar, F., Acuner, T. T., Çine, N., Öncü, F., Yeşilbursa, D., Özbek, U., & Türkcan, S. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-27 · Cited by 37
Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis
Kishi, T., Meltzer, H. Y., & Iwata, N. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000151 · Cited by 37
An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder
Burghardt, K. J., Evans, S. J., Wiese, K. M., & Ellingrod, V. L. (2015) · Clinical and Translational Science · doi:10.1111/cts.12324 · Cited by 35
Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
Sonnenschein, S. F., & Grace, A. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.009 · Cited by 37
Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis
Hecht, E. M., & Landy, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.030 · Cited by 36
Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5‐HT1Areceptor agonist
Piškulić, D., Olver, J. S., Maruff, P. T., & Norman, T. R. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1046 · Cited by 36
Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens
Arco, A. D., Mora, F., Mohammed, A. H., & Fuxé, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0533-3 · Cited by 36
QSPR Analysis of Drugs for Treatment of Schizophrenia Using Topological Indices
Zhang, X., Saif, M. J., Idrees, N., Kanwal, S., Parveen, S., & Saeed, F. (2023) · ACS Omega · doi:10.1021/acsomega.3c05000 · Cited by 35
The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia
Litman, R. E., Smith, M. A., Desai, D., Simpson, T., Sweitzer, D. E., & Kanes, S. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000071 · Cited by 35
An emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35
Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Edinoff, A. N., Silverblatt, N. S., Vervaeke, H., Horton, C. C., Girma, E., Kaye, A. D., Kaye, A. M., Kaye, J. S., Garcia, A. J., Neuchat, E. E., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4396 · Cited by 36
Mapping brain-behavior space relationships along the psychosis spectrum
Ji, J. L., Helmer, M., Fonteneau, C., Burt, J. B., Tamayo, Z., Demšar, J., Adkinson, B. D., Savić, A., Preller, K. H., Moujaes, F., et al. (2021) · eLife · doi:10.7554/elife.66968 · Cited by 42
Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors
Ueda, T., Ugawa, S., Ishida, Y., & Shimada, S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.007 · Cited by 35
Atypical Antipsychotics and a Src Kinase Inhibitor (PP1) Prevent Cortical Injury Produced by the Psychomimetic, Noncompetitive NMDA Receptor Antagonist MK-801
Dickerson, J., & Sharp, F. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300878 · Cited by 35
The Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidone
Álamo, C. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000117 · Cited by 35
Effects of depression and cognitive impairment on quality of life in older adults with schizophrenia spectrum disorder: results from a multicenter study.
Pascal de Raykeer, R., Hoertel, N., Blanco, C., Lavaud, P., Kaladjian, A., Blumenstock, Y., Cuervo-Lombard, C.-V., Peyre, H., Lemogne, C., Limosin, F., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.063 · Cited by 35
Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review
Masdrakis, V. G., & Baldwin, D. S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211002320 · Cited by 34
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
Ivanova, S. А., Paderina, D. Z., Freidin, M. B., Fedorenko, O. Y., Boiko, A. S., Pozhidaev, I. V., Semke, A. V., Bokhan, N. A., Agarkov, A. A., Wilffert, B., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1224926 · Cited by 34
Effect of second-generation antipsychotics on brain network topology in first-episode schizophrenia: A longitudinal rs-fMRI study
Wang, L., Guo, F., Zhu, Y., Wang, H., Liu, W.-M., Li, C., Wang, X., Cui, L., Xi, Y., & Yin, H. J. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.015 · Cited by 34
An organelle proteomic method to study neurotransmission‐related proteins, applied to a neurodevelopmental model of schizophrenia
Vercauteren, F., Flores, G., Ma, W., Chabot, J., Geenen, L., Clerens, S., Fazel, A., Bergeron, J. J. M., Srivastava, L. K., Arckens, L., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200700379 · Cited by 35
Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs
Pereira, A. M., Sugiharto-Winarno, A., Zhang, B., Malcolm, P., Fink, G., & Sundram, S. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001404 · Cited by 33
Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development
Kabbani, N., Woll, M. P., Nordman, J. C., & Levenson, R. G. (2011) · Current Drug Targets · doi:10.2174/138945012798868515 · Cited by 31
Association study of serotonergic gene variants with antipsychotic-induced adverse reactions
Al-Janabi, I. I., Arranz, M. J., Blakemore, A. I. F., Sáiz, P. A., Susce, M. T., Glaser, P. E. A., Clark, D. L., & de León, J. (2009) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283328dcd · Cited by 33
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology
Gogos, A., Bogeski, M., & van den Buuse, M. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830cd822 · Cited by 33
Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism
Mead, A., & Li, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102546 · Cited by 33
Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats
Terry, A. V., Warner, S., Vandenhuerk, L., Pillai, A., Mahadik, S. P., Zhang, G., & Bartlett, M. G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.030 · Cited by 33
Drugs in development for the treatment of schizophrenia
Emsley, R. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903066756 · Cited by 32
Recent advances of induced pluripotent stem cells application in neurodegenerative diseases
Amin, N., Tan, X., Ren, Q., Zhu, N., Botchway, B. O. A., Hu, Z., & Fang, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109674 · Cited by 36
Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions
Zádor, F., Nagy-Grócz, G., Kékesi, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Horváth, G., Benyhe, S., & Vécsei, L. (2019) · Molecules · doi:10.3390/molecules24203709 · Cited by 33
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats
Lin, E.-J. D., Lee, N. J., Slack, K., Karl, T., Duffy, L., O'Brien, E., Matsumoto, I., Dedova, I. V., Herzog, H., & Sainsbury, A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.006 · Cited by 32
The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms
Wyss, C., Hitz, K., Hengartner, M. P., Theodoridou, A., Obermann, C., Uhl, I., Roser, P., Grünblatt, E., Seifritz, E., Juckel, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068650 · Cited by 32
In Vivo Neurometabolic Profiling to Characterize the Effects of Social Isolation and Ketamine-Induced NMDA Antagonism: A Rodent Study at 7.0 T
Napolitano, A., Shah, K., Schubert, M. I., Porkess, V., Fone, K. C. F., & Auer, D. P. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt067 · Cited by 31
Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens
Manvich, D. F., Petko, A. K., Branco, R. C., Foster, S. L., Porter‐Stransky, K. A., Stout, K. A., Newman, A. H., Miller, G. W., Paladini, C. A., & Weinshenker, D. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0371-2 · Cited by 33
Clozapine-associated secondary antibody deficiency
Ponsford, M., Pecoraro, A., & Jolles, S. R. A. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000592 · Cited by 30
Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use
Guinart, D., Moreno, E., Galindo, L., Cuenca‐Royo, A., Barrera-Conde, M., Perez, E. J., Fernández-Avilés, C., Correll, C. U., Canela, E. I., Casadó, V., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa038 · Cited by 31
Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation
You, M., Bang, M., Park, H., Yang, B., Jang, K. B., Yoo, J., Hwang, D., Kim, M., Kim, B., Lee, S., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0802-1 · Cited by 33
Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders
Ibi, D., Nakasai, G., Koide, N., Sawahata, M., Kohno, T., Takaba, R., Nagai, T., Hattori, M., Nabeshima, T., Yamada, K., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00285 · Cited by 31
A Review of Antipsychotics and Priapism
Hwang, T. I. S., Shah, T., & Sadeghi‐Nejad, H. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.10.003 · Cited by 33
Clozapine induces astrocyte-dependent FDG-PET hypometabolism
Rocha, A., Bellaver, B., Souza, D. G., Schu, G., Fontana, I. C., Venturin, G. T., Greggio, S., Fontella, F. U., Schiavenin, M. L., Machado, L. S., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05682-3 · Cited by 31
Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment
Li, M., He, E., & Volf, N. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.007 · Cited by 31
Antipsychotic compounds differentially modulate high-frequency oscillations in the rat nucleus accumbens: a comparison of first- and second-generation drugs
Olszewski, M., Piasecka, J., Goda, S. A., Kasicki, S., & Hunt, M. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001034 · Cited by 31
A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia
Lin, C., Kuo, C.-C., Chou, L., Chen, Y.-H., Chen, C., Huang, K.-H., & Lane, H. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f28dff · Cited by 31
Analysis of Biogenic Amine Variability among Individual Fly Heads with Micellar Electrokinetic Capillary Chromatography−Electrochemical Detection
Powell, P. R., Paxon, T. L., Han, K., & Ewing, A. G. (2005) · Analytical Chemistry · doi:10.1021/ac050963m · Cited by 31
Clinical Pharmacology of Sleep
Pandi-Perumal, S. R., & Monti, J. M. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7440-3 · Cited by 31
Do peer-support groups for voice-hearers work? A small scale study of Hearing Voices Network support groups in Australia
Beavan, V., de Jager, A., & dos Santos, B. (2017) · Psychosis · doi:10.1080/17522439.2016.1216583 · Cited by 30
Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders
Esteban, S., & Garcı́a-Sevilla, J. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.007 · Cited by 30
Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review
Masana, M., Santana, N., Artigas, F., & Bortolozzi, A. A. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805289872 · Cited by 31
Regional brain volume changes following chronic antipsychotic administration are mediated by the dopamine D2 receptor
Guma, E., Rocchetti, J., Devenyi, G. A., Tanti, A., Mathieu, A., Lerch, J., Elgbeili, G., Courcot, B., Mechawar, N., Chakravarty, M., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.04.054 · Cited by 33
Clinical effectiveness of repetitive transcranial magnetic stimulation treatment in children and adolescents with neurodevelopmental disorders: A systematic review
Masuda, F., Nakajima, S., Miyazaki, T., Tarumi, R., Ogyu, K., Wada, M., Tsugawa, S., Croarkin, P. E., Mimura, M., & Noda, Y. (2019) · Autism · doi:10.1177/1362361318822502 · Cited by 30
Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review
Whitney, Z., Boyda, H. N., Procyshyn, R. M., Elbe, D., Black, T. R., Eslami, A., & Barr, A. M. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0044 · Cited by 30
A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates
Johnstone, A. L., Reierson, G. W., Smith, R. P., Goldberg, J. L., Lemmon, V., & Bixby, J. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.04.008 · Cited by 30
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
Preclinical models of antipsychotic drug action
Moreno, J. L., & González‐Maeso, J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000606 · Cited by 28
Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia—Relevance for Mental Diseases
Borroto‐Escuela, D. O., Ambrogini, P., Narváez, M., Liberto, V. D., Beggiato, S., Ferraro, L., Fores‐Pons, R., Alvarez‐Contino, J. E., López‐Salas, A., Mudò, G., et al. (2021) · Cells · doi:10.3390/cells10081902 · Cited by 29
A Case for Thalamic Mechanisms of Schizophrenia: Perspective From Modeling 22q11.2 Deletion Syndrome
Jiang, Y., Patton, M. H., & Zakharenko, S. S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.769969 · Cited by 32
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice
Moreno, J. L., Holloway, T. D., Umali, A., Rayannavar, V., Sealfon, S. C., & González‐Maeso, J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2809-7 · Cited by 29
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
Guo, X., Fang, M., Zhai, J., Wang, B., Wang, C., Hu, B., Sun, X., Lv, L., Lu, Z., Ma, C., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2242-3 · Cited by 29
Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action
Bay-Richter, C., O’Tuathaigh, C. M. P., O'Sullivan, G., Heery, D. M., Waddington, J. L., & Moran, P. M. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009656 · Cited by 29
Risperidone in Schizophrenia: Is There a Role for Therapeutic Drug Monitoring?
Seto, K., Dumontet, J., & Ensom, M. H. H. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182126d83 · Cited by 29
Rapid Identification of a Novel Small Molecule Phosphodiesterase 10A (PDE10A) Tracer
Hu, E., Ma, J., Biorn, C., Lester-Zeiner, D., Cho, R., Rumfelt, S., Kunz, R. K., Nixey, T. E., Michelsen, K., Miller, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002372 · Cited by 28
Recent Progress in Pharmacogenomics of Antipsychotic Drug Response
Zhang, J., & Malhotra, A. K. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0886-y · Cited by 28
HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia
Grubor, M., Živković, M., Šagud, M., Perković, M. N., Mihaljević-Peleš, A., Pivac, N., Mück‐Šeler, D., & Štrac, D. Š. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072345 · Cited by 27
New information of dopaminergic agents based on quantum chemistry calculations
Goode‐Romero, G., Winnberg, U., Domı́nguez, L., Ibarra, I. A., Vargas, R., Winnberg, E., & Martı́nez, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78446-4 · Cited by 28
Modulation of NMDA receptor function as a treatment for schizophrenia
Cioffi, C. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.019 · Cited by 28
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
Daneault, J., Carignan, B., Sadikot, A. F., Panisset, M., & Duval, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-76 · Cited by 29
Discovery of Novel Imidazo[4,5-b]pyridines as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A)
Hu, E., Andrews, K. L., Chmait, S., Zhao, X., Davis, C. D., Miller, S., Puppa, G. H. D., Dovlatyan, M., Chen, H., Lester-Zeiner, D., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5000993 · Cited by 28
Detection of the Moderately Beneficial Cognitive Effects of Low-Dose Treatment with Haloperidol or Clozapine in an Animal Model of the Attentional Impairments of Schizophrenia
Martínez, V., & Sarter, M. F. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301661 · Cited by 29
Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database
Kose, E., Uno, K., & Hayashi, H. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.16-00219 · Cited by 27
Pharmacogenetics in schizophrenia: a review of clozapine studies
Kohlrausch, F. B. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-0970 · Cited by 26
QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine
Brea, J. M., Castro, M., Loza, M. I., Masaguer, C. F., Raviña, E., Dezi, C., Pastor, M., Sanz, F., Cabrero-Castel, A., Galán-Rodríguez, B., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.021 · Cited by 27
Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients
Wei, Z., Wang, L., Xuan, J., Che, R., Du, J., Qin, S., Xing, Y., Gu, B., Yang, L., Li, H., et al. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.02.008 · Cited by 26
Metabolic effects of atypical antipsychotics: Molecular targets
Fonseca, M., Carmo, F., & Martel, F. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13347 · Cited by 26
Antipsychotic Drug Development
Kim, D. H., & Stahl, S. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_47 · Cited by 26
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
Catalán, R., González-Rodríguez, A., Penadés, R., García‐Rizo, C., Bioque, M., Parellada, E., & Bernardo, M. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s63948 · Cited by 26
System-based proteomic and metabonomic analysis of the Df(16)A+/− mouse identifies potential miR-185 targets and molecular pathway alterations
Wesseling, H., Xu, B., Want, E. J., Holmes, E. C., Guest, P. C., Karayiorgou, M., Gogos, J. A., & Bahn, S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.27 · Cited by 25
Schizophrenia-Related Microdeletion Impairs Emotional Memory through MicroRNA-Dependent Disruption of Thalamic Inputs to the Amygdala
Eom, T.-Y., Bayazitov, I. T., Anderson, K., Yu, J., & Zakharenko, S. S. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.002 · Cited by 27
Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature
Giordano, G. M., Brando, F., Pezzella, P., Angelis, M. D., Mucci, A., & Galderisi, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.970210 · Cited by 28
Curcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In Vitro
Canfrán‐Duque, A., Pastor, Ó., Reina, M., Lerma, M., Cruz-Jentoft, A. J., Lasunción, M. A., & Busto, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141829 · Cited by 26
Association of SNPs linked to increased expression of SLC1A1 with schizophrenia
Horiuchi, Y., Iida, S., Koga, M., Ishiguro, H., Iijima, Y., Inada, T., Watanabe, Y., Someya, T., Ujike, H., Iwata, N., et al. (2011) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31249 · Cited by 27
Visual hallucinations, thalamocortical physiology and Lewy body disease: A review
Esmaeeli, S., Murphy, K. P., Swords, G. M., Ibrahim, B. A., Brown, J. W., & Llano, D. A. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.06.006 · Cited by 26
Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model
Swalve, N. L., & Li, M. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32835651ea · Cited by 25
Emerging treatments in the management of schizophrenia – focus on sertindole
Zoccali, R. A. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6591 · Cited by 25
Aberrant Dopamine D2-Like Receptor Function in a Rodent Model of Schizophrenia
Perez, S. M., & Lodge, D. J. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193201 · Cited by 25
Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
Grace, A., & Uliana, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512374 · Cited by 26
SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells
Piao, L., Park, J., Li, Y., Shin, S., Shin, S., Kong, G., SHRESTHA, R., Tran, Q., Hur, G. M., Kim, J. L., et al. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1693 · Cited by 27
Use of Antipsychotics and Risk of Cerebrovascular Events in Schizophrenic Patients
Hsieh, P.-H., Hsiao, F., Gau, S. S., & Gau, C. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182900dfe · Cited by 26
Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia
Jaros, J. A. J., Rahmoune, H., Wesseling, H., Leweke, F. M., Özcan, S., Guest, P. C., & Bahn, S. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400148 · Cited by 24
Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior
Choy, K. H. C., Shackleford, D. M., Malone, D. T., Mistry, S. N., Patil, R. T., Scammells, P. J., Langmead, C. J., Pantelis, C., Sexton, P. M., Lane, J. R., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235788 · Cited by 25
Acute Clozapine Suppresses Synchronized Pyramidal Synaptic Network Activity by Increasing Inhibition in the Ferret Prefrontal Cortex
Gao, W. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00400.2006 · Cited by 24
Blood-Based Oxidation Markers in Medicated and Unmedicated Schizophrenia Patients: A Meta-Analysis
Goh, X. X., Tang, P. Y., & Tee, S. F. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102932 · Cited by 24
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
Carter, G. B. C., Milton, D. R., Ascher‐Svanum, H., & Faries, D. E. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-143 · Cited by 24
Iptakalim: A potential antipsychotic drug with novel mechanisms?
Sun, T., Zhao, C., Hu, G., & Li, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.024 · Cited by 24
Mechanisms Underlying Motivational Dysfunction in Schizophrenia
Saleh, Y., Barnham, I. J., Fernández-Egea, E., & Husain, M. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.709753 · Cited by 28
Factors related to missed first appointments after discharge among patients with schizophrenia in Taiwan
Cheng, K.-D., Huang, C., Tsang, H., & Lin, C. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.09.016 · Cited by 24
New Serotonin/Dopamine Antagonists for the Treatment of Schizophrenia
Miyake, N., Miyamoto, S., & Jarskog, L. F. (2012) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.6.3.4 · Cited by 25
Self-citation
Antipsychotic agents: efficacy and safety in schizophrenia
de Sena, E. P., Araújo, de Oliveira, I., & Juruena, M. F. (2012) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s37429 · Cited by 26
Qualitatively exploring hearing voices network support groups
Santos, B. D., & Beavan, V. (2015) · The Journal of Mental Health Training Education and Practice · doi:10.1108/jmhtep-07-2014-0017 · Cited by 24
Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors
Duan, X., Zhang, M., Zhang, X., Wang, F., & Lei, M. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.01.014 · Cited by 24
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia
Amato, D., Stasi, M. A., Borsini, F., & Nencini, P. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1229-1 · Cited by 24

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks